Charles Carroll Financial Partners LLC Has $1.36 Million Holdings in Stryker Co. (NYSE:SYK)

Charles Carroll Financial Partners LLC grew its stake in Stryker Co. (NYSE:SYK) by 20.2% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 4,530 shares of the medical technology company’s stock after buying an additional 760 shares during the quarter. Stryker makes up approximately 1.5% of Charles Carroll Financial Partners LLC’s portfolio, making the stock its 22nd largest holding. Charles Carroll Financial Partners LLC’s holdings in Stryker were worth $1,356,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Farmers & Merchants Trust Co of Chambersburg PA increased its position in Stryker by 203.3% in the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock worth $27,000 after buying an additional 61 shares during the period. Rogco LP bought a new position in Stryker during the fourth quarter worth $30,000. HBC Financial Services PLLC acquired a new position in Stryker during the 4th quarter valued at $37,000. Bourgeon Capital Management LLC bought a new stake in Stryker in the 4th quarter valued at $37,000. Finally, Operose Advisors LLC grew its position in Stryker by 308.6% in the 3rd quarter. Operose Advisors LLC now owns 143 shares of the medical technology company’s stock worth $39,000 after purchasing an additional 108 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on SYK. Roth Mkm increased their target price on shares of Stryker from $348.00 to $405.00 and gave the company a “buy” rating in a research note on Wednesday. Canaccord Genuity Group upgraded Stryker from a “hold” rating to a “buy” rating and raised their price objective for the stock from $315.00 to $360.00 in a research report on Wednesday, January 31st. Wells Fargo & Company boosted their price objective on Stryker from $364.00 to $381.00 and gave the company an “overweight” rating in a research report on Wednesday. Canaccord Genuity Group upgraded Stryker from a “hold” rating to a “buy” rating and set a $360.00 target price for the company in a research note on Wednesday, January 31st. Finally, Barclays lifted their price target on shares of Stryker from $372.00 to $376.00 and gave the stock an “overweight” rating in a research note on Thursday. Four analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and an average price target of $365.94.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 201,146 shares of the company’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the transaction, the director now owns 3,755,128 shares in the company, valued at approximately $1,287,633,391.20. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, Director Ronda E. Stryker sold 201,146 shares of the company’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the transaction, the director now owns 3,755,128 shares in the company, valued at approximately $1,287,633,391.20. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CAO William E. Berry, Jr. sold 7,690 shares of the company’s stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the transaction, the chief accounting officer now owns 3,675 shares in the company, valued at approximately $1,317,414. The disclosure for this sale can be found here. 5.90% of the stock is owned by corporate insiders.

Stryker Price Performance

Shares of NYSE:SYK traded up $1.82 on Friday, hitting $328.45. The stock had a trading volume of 1,589,424 shares, compared to its average volume of 1,415,127. Stryker Co. has a twelve month low of $249.98 and a twelve month high of $361.41. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.97 and a current ratio of 1.71. The firm’s 50 day moving average price is $346.99 and its 200-day moving average price is $317.29. The company has a market capitalization of $125.12 billion, a price-to-earnings ratio of 37.49, a price-to-earnings-growth ratio of 2.56 and a beta of 0.91.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, April 30th. The medical technology company reported $2.50 EPS for the quarter, beating the consensus estimate of $2.36 by $0.14. Stryker had a net margin of 16.03% and a return on equity of 23.05%. The company had revenue of $5.24 billion for the quarter, compared to the consensus estimate of $5.10 billion. During the same quarter in the previous year, the company earned $2.14 EPS. The firm’s revenue for the quarter was up 9.7% compared to the same quarter last year. On average, equities research analysts predict that Stryker Co. will post 11.94 earnings per share for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, April 30th. Investors of record on Friday, March 29th were given a dividend of $0.80 per share. The ex-dividend date of this dividend was Wednesday, March 27th. This represents a $3.20 annualized dividend and a yield of 0.97%. Stryker’s dividend payout ratio (DPR) is 36.53%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.